Optical biopsy to improve the diagnosis of kidney cancer: a prospective, observational, multicentre, in-vivo study.

Optical biopsy to improve the diagnosis of kidney cancer: a prospective, observational, multicentre, in-vivo study. - Optical biopsy to improve the diagnosis of kidney cancer

Status

Active, not recruiting

Phases

Phase 2

Study type

Observational

Source

NL-OMON

Registry ID

NL-OMON39685

Enrollment

194

Registered

2012-12-17

Start date

2013-08-08

Completion date

Unknown

Last updated

2024-04-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Kidney cancer renal mass

Interventions

None listed

Eligibility

Age

18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - Age >= 18 years - Solid, enhancing mass on cross sectional imaging suspect for RCC - Scheduled for nephrectomy, partial nephrectomy or cryoablation - Signed informed consent

Exclusion criteria

Exclusion criteria: Patients with a renal mass that are not candidates for active treatment.

Design outcomes

Primary

Measure	Time frame
Primary parameter To determine the accuracy of OB to differentiate renal tumor pathology from benign tissue by means of minimal invasive quantitative optical coherence tomography and diffuse reflectance spectroscopy.	—

Secondary

Measure	Time frame
Secondary parameters - To determine the differentiation capability of this combined technique to distinguish between the three most common RCC sub-types. - To determine whether OB is a good alternative to percutaneous biopsy for the diagnosing of renal cancer based upon accuracy and cost-effectiveness.	—

Countries

Netherlands

Outcome results